EYPT vs GENB: fair value comparison
EyePoint, Inc. and Generate Biomedicines, Inc. · Updated 2026-10-19
EYPT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. GENB has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, EYPT currently ranks higher by quality score.
| EYPT | GENB | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $2.99 | $12.09 |
| 12-month range | $2.99–$18.85 | $12.09–$16.50 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #186 of 301 Healthcare | #187 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | — |
| Revenue growth | Declining | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Downtrend | — |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: EYPT fair value analysis · GENB fair value analysis